PeptiterRequest Access
Pilot programme onboarding · 15 clinics · Q4 2026

Precision Peptide Therapy

Peptiter transforms continuous biomarker data — CGM, blood ketones, wearable RR intervals, and AI-administered assessments — into personalised peptide protocol recommendations that improve with every prescriber decision.

Request Clinic AccessView the Science
FDA CDS Exempt
AKS-Clean
Evidence-Gated ML
HIPAA Compliant
IRB Determined
39-D
Patient feature vector
3–5d
Wearing-off detection vs. 2 wk standard
≥0.70
Required AUROC at deploy gate
0
Per-prescription referral fees
§ 01Why Peptiter exists

Modern peptide prescribing flies on instruments from 1990.

01

Blind Prescribing

Peptide protocols are chosen from population averages. A 42-year-old keto-adapted male gets the same sermorelin dose as a 55-year-old on a standard diet. No continuous data informs the decision.

02

No Feedback Loop

After prescribing, clinicians wait 4–8 weeks for labs. CGM data, ketone dynamics, and wearable signals that could provide continuous metabolic feedback sit unused.

03

No Objective Mental-State Measurement

Standard HRV shows zero change during cognitive tasks. Subjective symptom reports arrive weeks late. Chaos indices from RR intervals detect state changes invisible to RMSSD and LF/HF — but nobody uses them yet.

§ 02Three products, one platform

One ChaosHRV engine. One prescriber dashboard. Three vertical workflows.

Each product shares the same ML flywheel — every prescriber decision sharpens recommendations across the platform.
MetabolicRx

Peptide Prescribing for Metabolic Health

  • 01KetoInsulinKit engine: OII (Overall Insulin Impact) score from CGM + blood ketone BHB suppression
  • 02Metabolic phenotyping: insulin sensitivity, GH axis status, ketosis depth, recovery capacity
  • 03Protocol optimisation: sermorelin, NAD+, tesamorelin, oxytocin dosing with full clinical rationale
"The OII score captures insulin demand dynamics in keto-adapted patients that no single lab value can."
Therapeutic targets
PEPTIDE / RX
Sermorelin
PEPTIDE / RX
NAD+
PEPTIDE / RX
Tesamorelin
PEPTIDE / RX
Oxytocin
Live monitoring stack
CGMBHBRR-intervalPHQ-9GAD-7SleepOIICIR
§ 03The Chaos Advantage

The Science: chaos indices detect what standard HRV cannot.

Mao, Okutomi & Umeno (2026), Scientific Reports · "Cognitive-Task-Induced Increase and Physical-Task-Induced Decrease in the Complexity of Heart Rate Variability"
Standard HRV during cognitive task
Δ from baseline
NO CHANGE
RMSSD+2%
LF/HF-2%
Chaos indices during cognitive task
Δ from baseline
SIGNIFICANT ↑
CD+42%
ApEn+38%
SampEn+56%
Fractal D.+28%

The Chaos Indicator Ratio (CIR)

CIR normalises chaotic complexity during an activity against the patient's own resting baseline. Different thresholds map to actionable clinical states.

CIR > 1.10
Cognitive engagement (medication working)
CIR < 0.85
Anxiety signature (Dimitriev 2016)
AM high · PM low
Stimulant wearing-off
CIR > 1.15 + RMSSD preserved
Flow state — therapeutic target
Indices computed
Chaos Degree (CD)Improved CD (ICD)ApEnSampEnHiguchi Fractal DimSD1/SD2 Poincaré

All of this from the same RR-interval data your patients' wearables already collect. Zero additional hardware.

Chaos Indicator Ratio
CIR 1.12
0.850.951.101.15
Interpretation
Cognitive engagement

Medication response detected. Patient is task-engaged.

Suggested clinical action
Maintain dose. Track CIR diurnal pattern.
0.60 anxiety1.00 rest1.30 flow
§ 04How it works

A four-stage pipeline. Auditable end-to-end.

01

Ingest

CGM stream (Libre, Dexcom), blood ketones (BHB), wearable RR intervals (Oura, Whoop, Apple Watch), lab panels, AI-administered questionnaires.

CGMBHBRRLabsQ&A
02

Phenotype

KetoInsulinKit (metabolic) + ChaosHRV (mental) + validated instruments → multi-dimensional patient phenotype. 39-dimensional feature vector.

OIICIRPHQ-9GAD-7
03

Recommend

Rules engine (live now) or Bayesian ML (after evidence gate) → specific peptide, dose, timing, route. Full clinical rationale displayed. Every recommendation is auditable.

Rules · liveBayesian · gated
04

Learn

You approve or override. Every decision is logged as labelled training data. Outcomes tracked at 4 and 8 weeks. The model improves with every patient you see.

Override log4w · 8w outcomes

The prescriber always has final authority. Peptiter is decision support — it augments your expertise, it doesn't replace it. Designed for CDS exemption from FDA device regulation under 21st Century Cures Act §520(o)(1)(E).

§ 05Business models

How clinics work with Peptiter.

B2B SaaS

Independent Clinics

$2,000–4,000/month flat
  • ✓Decision support dashboard
  • ✓Metabolic + chaos-based phenotyping
  • ✓Outcome tracking & analytics
  • ✓Use your own pharmacy
No per-patient fees. No per-prescription fees. Flat monthly license.
Contact sales →
Most embedded
White-label / API

Telehealth Platforms

Customengagement
  • ✓Embed Peptiter intelligence into your existing workflow
  • ✓API access to KetoInsulinKit + ChaosHRV engines
  • ✓White-label dashboard option
Your brand, our intelligence.
Contact sales →
Technology Partnership · 503A

Compounding Pharmacies

Flat feemonthly tech
  • ✓Electronic Rx routing integration
  • ✓Patient intake data formatting
  • ✓Platform access for your prescriber network
Not tied to script volume. Fair market value tech services.
Contact sales →
AKS-Clean Structure

No per-prescription referral fees. No drug revenue. Clean separation of clinical intelligence from pharmacy fulfillment. All agreements at fair market value per 42 C.F.R. §1001.952(d) safe harbour.

§ 06Evidence & clinical validation

Evidence-first, not growth-first.

Peptiter operates under a signed Research Charter with formal protocol, IRB determination, and staged evidence gates. The platform does not scale beyond pilot until evidence confirms safety, usability, and data completeness.

400
Min. evaluable outcomes
≥3
External validation clinics
150
External validation N
Locked
Model during prospective eval

Sample size per Riley et al. 2020. Model versions documented in a model card with training data hash, hyperparameters, and approval chain.

GateMetricThreshold
G1Rules → Pilot
Data completeness; Safety; Usability
≥80% evaluable; No severe AEs; SUS ≥68
G2Pilot → ML
Development sample; Override logging
≥400 outcomes (Riley); ≥90% complete
G3ML → Deploy
Discrimination; Calibration; Net benefit
AUROC ≥0.70; Cal slope 0.80–1.20; Positive NB
G4Deploy → Scale
Prospective response; Satisfaction
≥15pp improvement (p<0.05); SUS ≥68
§ 07Peptide catalogue

Every recommendation cites mechanism, evidence tier, and regulatory status.

Sermorelin
GHRH analogue
Adult GHD, longevity
SC
Compoundable
● Now
Observational▾
Mechanism
Stimulates pulsatile GH release via pituitary GHRH-R
Chaos monitoring expectation
Maintained baseline; sleep PSQI ↓
Questionnaires used
PSQI, ASRS
Key study
Walker 2019
NAD+
Coenzyme
Mitochondrial fatigue, depression adjunct
IV/SC
Investigational
● Now
Preclinical▾
Mechanism
NAD+ precursor; restores sirtuin activity
Chaos monitoring expectation
↑ in cognitive tasks within 2 wk
Questionnaires used
PHQ-9
Key study
Yoshino 2018
Oxytocin
Neuropeptide
Social anxiety, PTSD adjunct
IN
FDA approved (other indications)
● Now
Clinical Trial▾
Mechanism
OXT-R agonist; reduces amygdala reactivity
Chaos monitoring expectation
↑ during social tasks
Questionnaires used
GAD-7, LSAS
Key study
Guastella 2009
Tesamorelin
GHRH analogue
Visceral adiposity (HIV)
SC
FDA approved
● Now
Clinical Trial▾
Mechanism
Selective GHRH-R agonist; reduces VAT
Chaos monitoring expectation
n/a (metabolic primary)
Questionnaires used
—
Key study
Falutz 2007 NEJM
Selank
Anxiolytic peptide
GAD
IN
Investigational
● Now
Clinical Trial▾
Mechanism
TFR-derived heptapeptide; modulates GABA/serotonin
Chaos monitoring expectation
↑ from anxiety baseline (<0.85 → >1.0) within 3d
Questionnaires used
GAD-7, HARS
Key study
Zozulya 2008 (n=62)
Semax
Nootropic peptide
Cognitive enhancement, stroke recovery
IN
Investigational
● Now
Observational▾
Mechanism
ACTH(4-10) analogue; ↑ BDNF expression
Chaos monitoring expectation
↑ during executive tasks
Questionnaires used
ASRS, MoCA
Key study
Kaplan 2011
Semaglutide
GLP-1 agonist
T2DM, obesity, AUD
SC
FDA approved
○ Rx only
Clinical Trial▾
Mechanism
GLP-1R agonist; reduces reward salience
Chaos monitoring expectation
Stable; OII ↓
Questionnaires used
AUDIT-C
Key study
Klausen 2022 (AUD pilot)
Pinealon
Bioregulator peptide
Cognitive aging
SC
Investigational
● Now
Preclinical▾
Mechanism
Tripeptide; proposed epigenetic modulator
Chaos monitoring expectation
Insufficient data
Questionnaires used
MoCA
Key study
Khavinson 2011
BPC-157
Pentadecapeptide
GI/MSK healing
Oral/SC
Category 2 — pending reclassification
◐ Pending
Preclinical▾
Mechanism
Cytoprotective; angiogenesis modulator
Chaos monitoring expectation
n/a
Questionnaires used
—
Key study
Sikiric 2018 (animal)
PT-141
Melanocortin agonist
HSDD
SC/IN
FDA approved (Vyleesi)
● Now
Clinical Trial▾
Mechanism
MC4R agonist; central sexual response
Chaos monitoring expectation
n/a
Questionnaires used
FSFI
Key study
Kingsberg 2019
§ 08Who we serve

Built for prescribers who read PubMed before they read a brochure.

Longevity & Anti-Aging ClinicsFunctional Medicine PracticesTelehealth Peptide PlatformsCompounding Pharmacies (503A)ADHD & Mental Health ClinicsAddiction Medicine PracticesIntegrative Psychiatry
Early access clinician feedback coming Q4 2026.
Reserved · Pilot Clinic 1
Early access clinician feedback coming Q4 2026.
Reserved · Pilot Clinic 2
Early access clinician feedback coming Q4 2026.
Reserved · Pilot Clinic 3
§ 09Request access

Join the pilot programme.

We're onboarding 15 pilot clinics for our initial evidence programme. If you prescribe peptides and want data-driven decision support, we'd like to hear from you.

Products of interest

Your information is confidential and used only for pilot programme evaluation. Peptiter is HIPAA-compliant and operates under a signed Research Charter.